Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Other Operating Expenses (2024 - 2025)

Foghorn Therapeutics (FHTX) has 2 years of Other Operating Expenses data on record, last reported at $21.8 million in Q2 2025.

  • For Q2 2025, Other Operating Expenses rose 808.76% year-over-year to $21.8 million; the TTM value through Dec 2025 reached $21.8 million, up 12481.82%, while the annual FY2024 figure was -$6.2 million, N/A changed from the prior year.
  • Other Operating Expenses reached $21.8 million in Q2 2025 per FHTX's latest filing, up from $2.4 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $21.8 million in Q2 2025 and bottomed at -$2.6 million in Q1 2024.